MedTrace Logo

5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer

NCT01658813 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2018-03-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether the combination of a 5-Fluorouracil (5-FU) and interferon, which is able to stimulate the immune system to kill cancer cells, will help to increase tumor shrinkage in previously-treated metastatic gastrointestinal, kidney, or lung Cancer.

Conditions

  • Gastrointestinal Cancer Metastatic
  • Renal Cell Cancer Metastatic
  • Non Small Cell Lung Cancer Metastatic

Interventions

DRUG

5-Fluorouracil and Interferon

5-Fluorouracil Interferon-alfa-2b

Sponsors & Collaborators

  • Western Regional Medical Center

    lead OTHER

Principal Investigators

  • Walter Quan, MD · Western Regional Medical Center, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01658813 on ClinicalTrials.gov